NeoImmuneTech, Inc., a T cell-focused therapeutics company, was granted Orphan Drug Designation (ODD) from the U.S. FDA for NT-I7 (efineptakin alfa) (rhIL-7-hyFc) for the treatment of pancreatic cancer.   NT-I7 has been studied in several phase I and II clinical trials and has demonstrated the potential to amplify T cells across the subsets, boost the immune system, and enhance the anti-tumor response in people with pancreatic cancer and other solid tumors.   The FDA grants ODD status to med...